WO2010104306A2 - Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme - Google Patents

Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme Download PDF

Info

Publication number
WO2010104306A2
WO2010104306A2 PCT/KR2010/001444 KR2010001444W WO2010104306A2 WO 2010104306 A2 WO2010104306 A2 WO 2010104306A2 KR 2010001444 W KR2010001444 W KR 2010001444W WO 2010104306 A2 WO2010104306 A2 WO 2010104306A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
aryl
alkyl
methyl
Prior art date
Application number
PCT/KR2010/001444
Other languages
English (en)
Korean (ko)
Other versions
WO2010104306A3 (fr
Inventor
육종인
김현실
김남희
노경태
김수연
Original Assignee
주식회사 메디젠텍
사단법인 분자설계연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 메디젠텍, 사단법인 분자설계연구소 filed Critical 주식회사 메디젠텍
Publication of WO2010104306A2 publication Critical patent/WO2010104306A2/fr
Publication of WO2010104306A3 publication Critical patent/WO2010104306A3/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to a pharmaceutical composition for treating or preventing a disease caused by GSK3 migration from a cell nucleus to a cytoplasm containing a compound that inhibits the migration of GSK3 from the nucleus to the cytoplasm, and more particularly, to the cytoplasm in the nucleus.
  • the present invention relates to a pharmaceutical composition for inhibiting the growth or metastasis of cancer cells and a pharmaceutical composition for treating immunological diseases, which contain a novel compound that inhibits the migration of GSK3 to the stratum.
  • Glycogen synthase kinase-3 (GSK3) is a serine / threonine kinase and has a molecular weight of about 47 kD and phosphorylates 50 proteins.
  • GSK3 has two isoforms, GSK3 ⁇ and GSK3 ⁇ , and these genes are known to be very similar and very similar in function (Double BW & Woodgett. JR, J. Cell Sci., 116: 1175, 2003). .
  • GSK3 has numerous proteins, especially ⁇ -catenin or (1) in the course of (1) onset, (2) cancer development and progression, and (3) development of immune and chronic inflammatory diseases such as rheumatoid arthritis or It regulates the phosphorylation of proteins such as snail.
  • abnormality in signaling systems such as Wnt signaling promotes the development and progression of various diseases by increasing the half-life by inhibiting the phosphorylation of cancer-causing and metastatic activators such as ⁇ -catenin and snail by GSK3.
  • substances that promote the activity of GSK3 in cells or in the nucleus may be helpful in suppressing disease occurrence and progression by Wnt signaling.
  • increasing the activity of GSK3 can reduce the inhibition of GSK3 in the nucleus by Wnt signaling and effectively inhibit the onset and progression of many diseases caused by Wnt signaling.
  • the Axin gene has two isoforms, Axin1 and Axin2 (conductin).
  • the Axin1 and Axin2 genes are known to regulate protein phosphorylation through different transcriptional regulation processes.
  • the Axin gene acts as a negative regulator of Wnt signaling by promoting the phosphorylation of ⁇ -catenin by GSK3 and reducing its half-life (US Patent 2001 / 0052137A1).
  • FRAT-1 and FRAT-2 genes that bind to GSK3 to perform the nuclear export function of GSK3.
  • FRAT was found to be a GSK3 inhibitor, unlike Axin, which is known to promote ⁇ -catenin phosphorylation (Ciani, L. et al. , J. Cell Biol. , 164: 243, 2004; Yost, C. et al. ., Cell, 93: 1031, 1998), as well as GSK3 is different from the binding point and a binding form.
  • it is not related to Wnt at all, but knock-out of either Axin-1 or Axin-2 genes does not normally occur (Chia, IV & Costatini, F., Mol.
  • FRAT-1, -2, -3 can be knocked out in the normal occurrence (van Amerongen, R. et al. , Genes De., 19: 425, 2005) FRAT It is not yet clear what role genes play in Wnt signaling.
  • the present inventors have made diligent efforts to develop new compounds for treating diseases caused by a decrease in GSK3 concentration in the nucleus, resulting in novel compounds that inhibit GSK3 migration from the nucleus to the cytoplasm, and the compounds in the nucleus.
  • the present invention has been found to be useful in treating various diseases caused by decreasing GSK3 concentration.
  • Another object of the present invention to provide a pharmaceutical composition for the treatment or prevention of diseases caused by GSK3 migration from the cell nucleus to the cytoplasm containing the compound as an active ingredient.
  • Still another object of the present invention is to provide a pharmaceutical composition for inhibiting growth or metastasis of cancer cells containing the compound as an active ingredient.
  • Still another object of the present invention is to provide a pharmaceutical composition for treating an immunological disease containing the compound as an active ingredient.
  • the present invention provides a method for treating diseases caused by GSK3 migration from the cell nucleus to the cytoplasm containing the compound represented by the following formula (I), a pharmaceutically acceptable salt, prodrug, or isomer thereof as an active ingredient.
  • pharmaceutical compositions for treatment or prophylaxis are provided:
  • A is CR a or N
  • D is CR d or N
  • G is CR g or N
  • J is CR j or N
  • Y is Y 1 ( ) Or Y 2 ( );
  • M is CR m or N
  • Q is CR q or N
  • R a , R d , R g , R j , R w , R m , R q and R z are each independently hydrogen, halogen, -CN, -NO 2 , -C (O) OH, -C (O ) H, -OH, substituted or unsubstituted -C (O) O-alkyl, substituted or unsubstituted -C (O) O-aryl, substituted or unsubstituted -C (O) O-hetero Aryl, substituted or unsubstituted -C (O) -alkyl, substituted or unsubstituted -C (O) -aryl, substituted or unsubstituted -C (O) -heteroaryl, substituted or unsubstituted Substituted carboxamido, substituted or unsubstituted carbonylamino, substituted or unsubstituted sulf
  • the present invention also provides a pharmaceutical composition for inhibiting the growth or metastasis of cancer cells containing the compound represented by Formula 1, a pharmaceutically acceptable salt, prodrug, or isomer thereof as an active ingredient.
  • FIG. 1 is a schematic diagram showing the activation of ⁇ -catenin, increased Axin2 expression, and GSK3 regulation in the nucleus by Wnt signaling.
  • Figure 2 is a schematic diagram of the process of concentration control of nuclear GSK3 by nuclear signaling by Wnt signaling.
  • FIG. 3 is a schematic diagram of the binding structure of Axin and GSK3.
  • Figure 4 shows the results of analyzing the activity of the compounds represented by 41, 45, 78, 80, 81, 82, 95, 147 and 149 according to the present invention Axin2 through the expression of GSK3 ⁇ .
  • alkyl refers to a saturated straight or branched ratio having 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, most preferably 1 to 4 carbon atoms.
  • -Means a cyclic hydrocarbon.
  • saturated straight chain alkyls include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, -n-nonyl and -n-decyl, and saturated branched alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, tert-butyl, -isopentyl, 2- Methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,3-d
  • Alkyl groups may be unsubstituted or substituted. Alkyl groups can be specified as having a certain number of carbon atoms. For example, an alkyl group having 1 to 8 carbon atoms may be specified as a C1-C8 alkyl group, while an alkyl group having 1 to 6 carbon atoms may be specified as a C1-C6 alkyl group.
  • the symbol "-" denotes the point of attachment to the rest of the molecule, wherein one of the hydrogens of the alkyl group is associated with an aryl group. It is substituted with a bond.
  • -(C 1 -C 2 alkyl) aryl includes groups such as —CH 2 Ph, —CH 2 CH 2 Ph and —CH (Ph) CH 3 .
  • alkenyl refers to an unsaturated straight or branched non-cyclic hydrocarbon having 2 to 20 carbon atoms and one or more carbon-carbon double bonds. Preferably alkenyl has 2 to 10 carbon atoms.
  • Exemplary straight-chain alkenyls include, but are not limited to, -but-3-ene, -hex-4-ene and -oct-1-ene.
  • Exemplary branched alkenyls include, but are not limited to, 2-methyl-but-2-ene, -1-methyl-hex-4-ene and -4-ethyl-oct-1-ene Can be.
  • Alkenyl groups may be substituted or unsubstituted.
  • Alkenyl groups can be specified as having a certain number of carbon atoms. For example, alkenyl groups having 2 to 8 carbon atoms can be specified as C 2 -C 8 alkenyl groups, while alkenyl groups with 2 to 6 carbon atoms can be specified as C 2 -C 6 alkenyl groups.
  • alkynyl means an alkyl group wherein one or more carbon-carbon single bonds are replaced with the same number of carbon-carbon triple bonds. Alkynyl groups must contain two or more carbon atoms and can be substituted or unsubstituted. Alkynyl groups can be specified as having a certain number of carbon atoms. For example, an alkynyl group having 2 to 8 carbon atoms may be specified as a C 2 -C 8 alkynyl group, while an alkynyl group having 2 to 6 carbon atoms may be specified as a C 2 -C 6 alkynyl group.
  • oxo means a ⁇ O group.
  • hydroxy and hydroxyl refer to an -OH group.
  • hydroxyalkyl as used herein, means an alkyl group wherein at least one hydrogen is substituted with a hydroxyl group.
  • hydroxyalkenyl as used herein refers to an alkenyl group in which one or more hydrogens are substituted with hydroxyl groups.
  • hydroxyalkynyl as used herein, means an alkynyl group in which one or more hydrogens are substituted with a hydroxyl group.
  • Alkoxy means the structure of formula -O-alkyl, wherein alkyl has the meanings described above.
  • Haloalkoxy means an alkoxy group wherein at least one hydrogen has been replaced with a halogen atom.
  • Hydroxyalkoxy means an alkoxy key in which at least one hydrogen is substituted with a hydroxy group.
  • Alkylsulfonyl means the structure of the formula -S (O) 2 -alkyl.
  • Amino refers to the -NH 2 group.
  • Alkylamino and dialkylamino refer to the structures of the formula -NH-alkyl and -N (alkyl) alkyl, respectively, wherein alkyl is as defined above.
  • the alkyl groups in the dialkylamino groups can be the same or different.
  • Alkylsulfonyl amino refers to the structure of the formula -NHS (O) 2 -alkyl.
  • Carbocyclic ring system and “carbocyclic” refer to ring systems in which all ring members are carbon atoms. Carbocyclic ring systems typically contain 3 to 14 ring atoms. Carbocyclic ring systems may be aromatic or non-aromatic. Carbocyclic ring systems include cycloalkyl rings and may also include fused ring systems. Examples of fused ring carbocyclic ring systems include, but are not limited to, decalin, norbornane, tetrahydronaphthalene, naphthalene, indene and adamantane. Ring atoms in the carbocyclic ring system may be substituted or unsubstituted.
  • heterocyclic ring refers to a carbocyclic ring system in which one or more ring atoms is a hetero atom such as N, O, S or Si.
  • the heterocyclic ring system includes 1 to 4 hetero atoms.
  • the hetero atom is selected from N, O or S.
  • Heterocyclic ring systems can include one ring or a fused ring system.
  • the heterocyclic ring system may comprise two six membered rings fused to each other, or may comprise one five membered ring and one six membered ring fused to each other.
  • Heterocyclic ring systems can be aromatic or non-aromatic, and can be unsaturated, partially unsaturated or saturated. Ring atoms in the heterocyclic ring system may be substituted or unsubstituted.
  • aryl refers to a carbocyclic ring or ring system containing 6 to 14 ring atoms wherein at least one ring is aromatic.
  • the ring atoms of the carbocyclic aryl group are all carbon atoms.
  • Aryl groups include mono-, bi- and tricyclic groups, as well as benzo-fused carbocyclic moieties such as, but not limited to, 5,6,7,8-tetrahydronaphthyl and the like.
  • the aryl group is a monocyclic ring or bicyclic ring.
  • aryl groups include, but are not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, phenanthrenyl and naphthyl.
  • the aryl group can be unsubstituted or substituted.
  • heteroaryl means an aryl group in which one or more, but not all, ring carbon atoms in any ring that is aromatic or non-aromatic is substituted with a hetero atom.
  • pyridine is a heteroaryl group, such as a compound in which benzene is fused to a non-aromatic ring containing one or more hetero atoms.
  • exemplary hetero atoms are N, O, S and Si.
  • the hetero atom is N, O or S.
  • Heteroaryl groups can be unsubstituted or substituted.
  • Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazolyl, 3- Pyrazolyl, 5-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-iso Sazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furanyl, 3-furanyl, dibenzofuryl, 2-thienyl (2 -Thiophenyl), 3-thienyl (3-thiophenyl), 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidiny
  • Non-limiting examples of other heteroaryl groups include pyridyl, indazolyl, isoquinolinyl, thiazolopyridinyl, benzothiazolonyl, dihydroquinolinonyl, benzoisoxazolyl, benzooxazoloyl, indolinonyl, Benzoimidazolonyl, phthalazinyl, naphthyridinyl, thienopyridinyl, benzodioxolyl, isoindolinonyl, quinazolinyl or cinnaolinyl.
  • cycloalkyl refers to an unsaturated or saturated hydrocarbon that forms one or more rings having 3 to 20 ring carbon atoms, and in some embodiments 3 to 10, 3 to 8 or 3 to 6 ring carbon atoms do.
  • the ring in the cycloalkyl group is non-aromatic. Cycloalkyl groups can be unsubstituted or substituted.
  • a compound of the present invention may be optionally substituted with one or more substituents, such as those generally exemplified above or exemplified by certain classes, subclasses and species of the present invention.
  • substituents such as those generally exemplified above or exemplified by certain classes, subclasses and species of the present invention.
  • substituted refers to the substitution of a hydrogen radical in a given structure with a radical of a specified substituent, whether or not preceded by "optionally”.
  • an optionally substituted group may have a substituent at each substitutable position of the group, and if more than one position in any given structure may be substituted with more than one substituent selected from the specified group, such substituents May be the same or different at all positions.
  • Combinations of substituents contemplated in the present invention are preferably combinations which lead to the formation of stable or chemically suitable compounds.
  • "for inhibiting the growth or metastasis of cancer cells” means “anticancer”. That is, it means the action of inhibiting or killing the proliferation of cancer cells and the action of inhibiting or blocking the metastasis of cancer cells, and means both prevention and treatment of cancer.
  • prevention refers to any action that inhibits cancer formation or delays the onset of administration of the composition
  • treatment refers to any action that improves or advantageously changes the symptoms of the disease by administration of the composition. It means.
  • treatment includes (i) preventing the disease, disorder or symptom in a mammal that may be susceptible to disease, disorder and / or symptom but cannot yet be diagnosed with it; (ii) inhibiting a disease, disorder or symptom, ie, arresting their onset; And (iii) alleviating a disease, disorder or symptom, ie, causing regression of one or more of the disease, disorder and / or symptoms, or signs thereof.
  • prevention also specifically refers to the ability of a compound or composition of the invention to prevent such a disease in a mammal diagnosed with or at risk of developing the disease identified herein. The term also includes preventing further progression of the disease in a mammal already suffering from or having signs of the disease.
  • containing as an active ingredient is meant to contain a “therapeutically effective amount” or “prophylactically effective amount” of a compound represented by the formula (1) according to the present invention, a pharmaceutically acceptable salt, prodrug or isomer thereof.
  • a “therapeutically effective amount” is a compound of the invention sufficient to provide an advantage in the treatment or prevention of a symptom or disease, such as cancer, to delay or minimize a symptom associated with the symptom or disease, or to treat or ameliorate a disease or cause thereof. Or the amount of a prodrug thereof.
  • a therapeutically effective amount means an amount sufficient to provide a therapeutic benefit in vivo.
  • prophylactically effective amount refers to an amount of a compound of the present invention or other active ingredient sufficient to prevent a symptom or disease, such as cancer, or recurrence or metastasis of the cancer.
  • a prophylactically effective amount refers to an amount sufficient to prevent the initial disease, or recurrence or spread of the disease.
  • the term “preferably” includes non-toxic amounts that improve overall prophylaxis or enhance or synergize with the prophylactic efficacy of another prophylactic or therapeutic agent.
  • the term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases, including inorganic and organic acids and bases.
  • the compound of formula 1 is a base, any suitable method available in the art, for example, treatment of the free base with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or the like, or organic acids such as acetic acid, male Acids, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acid such as glucuronic acid or galacturonic acid, alpha-hydroxy acid such as citric acid or tartaric acid, amino acids such as aspartic acid Or by treating with glutamic acid, aromatic acid such as benzoic acid or cinnamic acid, sulfonic acid such as p-toluenesulfonic
  • any suitable method is preferred, for example by treating the free acid with an inorganic or organic base such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or an alkaline earth metal hydroxide or the like.
  • Phase acceptable salts can be prepared.
  • suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary and tertiary amines, and cyclic amines such as piperidine, morpholine and piperazine, and sodium, calcium, Inorganic salts derived from potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
  • the salt can be contacted with a base or an acid in a conventional manner and the parent compound can be isolated to regenerate the neutral form of the compound from the salt.
  • the parent form of the compound differs from some physical properties, such as various salt forms, solubility in polar solvents, for the purposes of the present invention, the salt is equivalent to the parent form of the compound.
  • prodrug means any chemical that is converted to various therapeutically effective chemicals after administration.
  • Prodrugs of the compounds described herein are compounds that readily change chemically under physiological conditions to provide the compounds of the present invention.
  • Prodrugs may also be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, if a prodrug is present with a suitable enzyme or chemical reagent in a transdermal patch reservoir, it may be slowly converted to a compound of the present invention.
  • Prodrugs are often useful because, in some cases, they may be easier to administer than the parent drug. For example, prodrugs are available in vivo by oral administration, while parent drugs are not.
  • Prodrugs may also have improved solubility in pharmaceutical compositions compared to the parent drug.
  • Various prodrug derivatives such as derivatives based on hydrolytic or oxidative activation of prodrugs, are known in the art.
  • Non-limiting examples of prodrugs will be compounds of the invention that are administered as esters ("prodrugs"), but then metabolically hydrolyzed with an active substance called carboxylic acid. Further examples include peptidyl derivatives of the compounds.
  • the compounds of the present invention may contain one or more asymmetric centers and may therefore exist in racemic and racemic mixtures, scalemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. have. All such isomeric forms of these compounds are expressly included in the present invention.
  • optically pure or “stereoisomericly pure” means a composition comprising one stereoisomer of a compound and substantially free of other stereoisomers of that compound.
  • a stereoisomerically pure compound having one chiral center will be substantially free of the opposite enantiomers of the compound.
  • a typical stereoisomerically pure compound is greater than about 80 weight percent of one isomer of the compound, less than about 20 weight percent of the other stereoisomer of the compound, more preferably greater than about 90 weight percent of one stereoisomer of the compound, Less than about 10 weight percent of stereoisomers, even more preferably more than about 95 weight percent of one stereoisomer of the compound, less than about 5 weight percent of the other stereoisomers of the compound, most preferably about 97 weight of one stereoisomer of the compound Greater than weight percent and less than about 3 weight percent of other stereoisomers of the compound.
  • the present invention encompasses the use of stereoisomericly pure forms of such compounds as well as the use of mixtures of these forms.
  • mixtures comprising the same or non-equivalent amounts of enantiomers of certain compounds of the invention can be used in the methods and compositions of the invention.
  • isomers can be synthesized asymmetrically or cleaved using standard techniques such as chiral columns or chiral splitting agents (see, eg, Jacques, J., et al, Enantiomers, Racemates and Resolution (Wiley-lnterscience). , New York, 1981); Wilen, SH, et al.
  • Some compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are within the scope of the present invention.
  • GSK3 tau protein kinase (TPK I), FA factor (Factor A) kinase, kinase FA and ATP-citrate lyase kinase (ACLK).
  • Glycogen synthase kinase 3 present in two isotypes, GSK3 ⁇ and GSK3 ⁇ , is a proline-associated serine / threonine kinase originally identified as an enzyme that phosphorylates glycogen synthase.
  • GSK3 is a glycogen synthase, phosphatase inhibitor I-2, type II subunit of cAMP-dependent protein kinase, G-subunit of phosphatase-1, acetyl coenzyme A carboxylase, myelin basic protein, microtubule- Related protein, neurofibrillary protein, M-CAM cell adhesion molecule, nerve growth factor receptor, c-Jun transcription factor, JunD transcription factor, c-Myb transcription factor, c-Myc transcription factor, L-Myc transcription factor, adenomatous It has been demonstrated to phosphorylate many proteins in vitro, such as polyposis tumor suppressor protein, tau protein and ⁇ -catenin.
  • the various proteins described above that can be phosphorylated by GSK3 mean that GSK3 is involved in a number of metabolic and regulatory processes in the cell.
  • the "disease caused by GSK3 migration from the cell nucleus to the cytoplasm” is a disease mediated through GSK3, for example, cancer, diabetes mellitus, Niemann Pick's disease type C , Bipolar disorder (particularly manic depression), Alzheimer's disease, FTDP-17 (frontal temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple systemic atrophy atrophy, Pick's disease, dementia Pugilistica, AIDS associated dementia, dementia, stroke, Guam parkinsonism-dementia complex, post-inflammation Parkinson Postencephalic Parkinsonism, frontal lobe degeneration, argyrophilic grains disease, depression, Schizophrenia, Huntington's disease, myotonic dysfunction Myotonic dystrophy, subacute sclerotizing panencephalitis, prion disease, Down's syndrome, allergy or asthma, multiple sclerosis, rheumatoid arthritis, arterio
  • the signaling mechanism proposed by the present invention suggests a new therapeutic effect and concept of the ⁇ -catenin targeted therapeutic agent that has been developed or developed in the future.
  • As a method of inhibiting the activity of ⁇ -catenin it is known to inhibit the ⁇ -catenin transcriptional regulation by competitively binding to ⁇ -catenin transcription complexes, that is, LEF / TCF, CBP300 and the like. In this case, most of the drugs developed so far have been expected to induce apoptosis of cells by targeting ⁇ -catenin.
  • Wnt signaling reduces the expression of E-cadherin, increases the expression of ⁇ -catenin and Snail, and invades growth or metastasis of cancer cells.
  • Snail phosphorylation control process by ⁇ -catenin is as shown in FIG. Briefly, the expression of Axin is increased by ⁇ -catenin, and Axin binds to GSK3 inside the nucleus and transfers GSK3 into the cytoplasm. This increases the expression of Snail and metastasis of cancer cells occurs.
  • 2 is a schematic diagram illustrating the GSK3 concentration control process in the nucleus by Wnt signaling.
  • the activation of ⁇ -catenin gene induces Axin2 gene expression, and the Axin2 gene binds to GSK3 present in the cell nucleus to perform the nuclear export function of GSK3, thereby reducing the concentration of GSK3 in the nucleus.
  • the expression of the Snail gene which is phosphorylated and degraded by GSK3, is increased.
  • increased expression of the Snail gene by Wnt signaling induces invasive growth and metastasis of cancer cells, and clinically causes continuous recurrence and distant metastasis.
  • Figure 3 shows the binding structure of Axin and GSK3, it can be seen that Axin binds to GSK3 by Axin-derived peptide fragment (370-390 amino acid sequence of hAxin2) (Dajani et al. , EMBOJ ., 22: 494, At this time, Axin and FRAT proteins have ⁇ -helix structure, and the intermediate hydrophobic residues bind to the groove structure of GSK3, and the compound that can competitively bind is the nuclear export function of GSK3 by Axin or FRAT.
  • Axin-derived peptide fragment 370-390 amino acid sequence of hAxin2
  • Axin and FRAT proteins have ⁇ -helix structure, and the intermediate hydrophobic residues bind to the groove structure of GSK3, and the compound that can competitively bind is the nuclear export function of GSK3 by Axin or FRAT.
  • amino acids 383-401 of Axin1 which are known to bind GSK3 so far, are the helix (262-273) and extended loop (amino acid 285) of GSK3 ⁇ . 299), it was found to bind to a groove formed.
  • hydrophobic ridges consisting of residues of phenylalanine 388 (Phe388), leucine 392 (Leu392), leucine 396 (Leu396) and valine 399 (Val399) play a crucial role in binding to GSK3 ⁇ .
  • Axin1 and Axin2 have very similar structures and similar functions to transfer GSK3 into the cytoplasm inside the nucleus.
  • Axin1 and Axin2 seem to have the same function, ie very similar structure, because Axin1 and Axin2 can be replaced in the developmental process (Chia, IV & Cos tantini, F., Mol. Cell Biol. , 25: 4371,2005).
  • the present inventors induce the expression of Axin1 or Axin2 in cells, and the expression of the Snail protein, which is phosphorylated and degraded by GSK3, is strongly reduced. We have seen an increase.
  • the present invention has a fundamentally different concept from the development of various compounds for inhibiting existing phosphatase. That is, the compound described in the present invention is fundamentally different from the conventional phosphatase inhibition in that it increases the GSK3 kinase activity inside the cell nucleus by inhibiting the nuclear export function of GSK3 by Axin, rather than inhibiting the kinase domain. The concept is different.
  • the present inventors first analyzed the X-ray structure of GSK3-Axin2 to develop a new inhibitor that inhibits the binding of GSK3 and Axin2, and through this, the structural and functional pharmacophore of Axin2 binding to GSK3 Obtained new information on On the basis of this, 32 compounds of the final product obtained through various stages of organic chemical reaction were obtained, and their structure was confirmed through NMR and Mass experiment equipment. The compounds with high fitness scores were selected for the pharmacophore, and the expected pharmacological activity of the selected compounds was predicted through docking studies. The actual pharmacological activity of the compounds was confirmed by in vitro screeening experiments.
  • the present invention provides a composition for inhibiting GSK3 migration from the nucleus to the cytoplasm comprising a compound represented by the following Chemical Formula 1, a pharmaceutically acceptable salt, a prodrug, or an isomer thereof, in other words, from the nucleus to the cytoplasm.
  • A is CR a or N
  • D is CR d or N
  • G is CR g or N
  • J is CR j or N
  • Y is Y 1 ( ) Or Y 2 ( );
  • M is CR m or N
  • Q is CR q or N
  • R a , R d , R g , R j , R w , R m , R q and R z are each independently hydrogen, halogen, -CN, -NO 2 , -C (O) OH, -C (O ) H, -OH, substituted or unsubstituted -C (O) O-alkyl, substituted or unsubstituted -C (O) O-aryl, substituted or unsubstituted -C (O) O-hetero Aryl, substituted or unsubstituted -C (O) -alkyl, substituted or unsubstituted -C (O) -aryl, substituted or unsubstituted -C (O) -heteroaryl, substituted or unsubstituted Substituted carboxamido, substituted or unsubstituted carbonylamino, substituted or unsubstituted sulf
  • R a is hydrogen, halogen, substituted or unsubstituted alkyl, halogen substituted alkyl, including -CF 3 , Substituted or unsubstituted-(CH 2 ) n -N (R)-(CH 2 ) n -alkoxy;
  • N is each independently an integer of 0 to 6;
  • Each R is independently hydrogen, halogen, -CN, -NO 2 , -C (O) OH, -C (O) H, -OH, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl Or substituted or unsubstituted aryl and substituted or unsubstituted amino.
  • R a is-(CH 2 ) n -C (O) OH, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted morpholinyl, substituted Or unsubstituted-(CH 2 ) n -C (O) O- (CH 2 ) n -alkyl, substituted or unsubstituted-(CH 2 ) n -C (O) O- (CH 2 ) n -Aryl, substituted or unsubstituted-(CH 2 ) n -C (O) O- (CH 2 ) n -heteroaryl, substituted or unsubstituted -Z a -alkyl, substituted or unsubstituted- Z a -cycloalkyl, substituted or unsubstituted -Z a -heterocycloalkyl, substituted or unsubstit
  • Z a is each independently-(CH 2 ) n- C (O) N (R)-(CH 2 ) n or-(CH 2 ) n -N (R) C (O)-(CH 2 ) n Can be.
  • R a is - (CH 2) n- CN, - (CH 2) n -NO 2, - (CH 2) n -C (O) H, - (CH 2) n -OH, Substituted or unsubstituted-(CH 2 ) n -C (O) -alkyl, substituted or unsubstituted-(CH 2 ) n -C (O) -aryl, substituted or unsubstituted-(CH 2 ) n -C (O) -heteroaryl, substituted or unsubstituted primary, secondary, tertiary amine, or substituted or unsubstituted heterocyclic nonaromatic ring.
  • R d may be hydrogen or halogen.
  • R d is-(CH 2 ) n -NO 2 ,-(CH 2 ) n -SO 3 H, substituted or unsubstituted-(CH 2 ) n -alkoxy, substituted or unsubstituted Alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted -Z a -alkyl, substituted or unsubstituted -Z a -cycloalkyl, substituted or unsubstituted -Z a -heterocycloalkyl, substituted or unsubstituted -Z a -cycloalkylalkyl, substituted or unsubstituted -Z a -arylalkyl, substituted or unsubstituted -Z a -aryl, substituted or unsubstituted -Z a -aryl, substituted or unsubstitute
  • Z a is each independently-(CH 2 ) n- C (O) N (R)-(CH 2 ) n or-(CH 2 ) n -N (R) C (O)-(CH 2 ) n ego;
  • Z b are each independently — (CH 2 ) N —S (O) 2 N (R) — (CH 2 ) n — or — (CH 2 ) n —N (R) S (O) 2 — (CH 2 ) n -may be.
  • R d is-(CH 2 ) n -CN,-(CH 2 ) n -C (O) OH,-(CH 2 ) n -C (O) H,-(CH 2 ) n -OH, substituted or unsubstituted-(CH 2 ) n -C (O) -alkyl, substituted or unsubstituted-(CH 2 ) n -C (O) -aryl, substituted or unsubstituted- (CH 2 ) n -C (O) -heteroaryl, substituted or unsubstituted primary, secondary, tertiary amine, or substituted or unsubstituted heterocyclic nonaromatic ring.
  • R g is hydrogen, substituted or unsubstituted-(CH 2 ) n -pyridyl, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted Heteroaryl.
  • the R g Is halogen,-(CH 2 ) n -NO 2 ,-(CH 2 ) n -C (O) OH,-(CH 2 ) n -C (O) -N (R) 2 , Substituted or unsubstituted alkyl- (CH 2 ) n -NO 2 , Substituted or unsubstituted aryl- (CH 2 ) n -NO 2 , Substituted or unsubstituted heteroaryl- (CH 2 ) n -NO 2, Substituted or unsubstituted alkyl- (CH 2 ) n -C (O) OH, substituted or unsubstituted aryl- (CH 2 ) n -C (O) OH, substituted or unsubstituted heteroaryl- (CH 2 ) n -C (O) OH, substituted or unsubstituted alkyl- (CH
  • Z a is each independently-(CH 2 ) n- C (O) N (R)-(CH 2 ) n or-(CH 2 ) n -N (R) C (O)-(CH 2 ) n ego;
  • Z b are each independently — (CH 2 ) n —S (O) 2 N (R) — (CH 2 ) n — or — (CH 2 ) n —N (R) S (O) 2 — (CH 2 ) n- ;
  • Z c are each independently C (R) or N;
  • M may be each independently 0, 1 or 2.
  • R g is-(CH 2 ) n- CN,-(CH 2 ) n C (O) H,-(CH 2 ) n -OH, substituted or unsubstituted-(CH 2 ) n- C (O) -alkyl, substituted or unsubstituted-(CH 2 ) n -C (O) -aryl, substituted or unsubstituted-(CH 2 ) n -C (O) -heteroaryl, Or a substituted or unsubstituted heterocyclic nonaromatic ring.
  • R j is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or Unsubstituted (CH 2 ) n -N (R)-(CH 2 ) n -aryl, or substituted or unsubstituted-(CH 2 ) n -N (R)-(CH 2 ) n -heteroarylyl Can be.
  • R j is-(CH 2 ) n -CN,-(CH 2 ) n -NO 2 ,-(CH 2 ) n -C (O) OH,-(CH 2 ) n -C ( O) H,-(CH 2 ) n -OH, substituted or unsubstituted-(CH 2 ) n -C (O) -alkyl, substituted or unsubstituted-(CH 2 ) n -C (O) -Aryl, substituted or unsubstituted-(CH 2 ) n -C (O) -heteroaryl, substituted or unsubstituted-(CH 2 ) n -alkoxy, substituted or unsubstituted primary, secondary , Tertiary amine or substituted or unsubstituted heterocyclic nonaromatic ring.
  • R w is hydrogen, halogen,-(CH 2 ) n -CN,-(CH 2 ) n -NO 2 ,-(CH 2 ) n -C (O) OH,-(CH 2 ) n- C (O) H,-(CH 2 ) n -OH, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl , Substituted or unsubstituted-(CH 2 ) n -C (O) -alkyl, substituted or unsubstituted-(CH 2 ) n -C (O) -aryl, substituted or unsubstituted-(CH 2 ) n- C (O) -heteroaryl, substituted or unsubstituted-(CH 2 ) n -alkoxy, substituted or unsub
  • R m , R q and R z are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -T 1 -T 2 -T 3 -T 4 or ego;
  • Each T 1 is independently a covalent bond,-(CH 2 ) n -,-(CH 2 ) n -O- (CH 2 ) n -,-(CH 2 ) n -S- (CH 2 ) n- , -(CH 2 ) n -N (R)-(CH 2 ) n -,-(CH 2 ) n -S (O) p- (CH 2 ) n -,-(CH 2 ) n -C (O) -(CH 2 ) n -,-(CH 2 ) n -C (O) O- (CH 2 ) n -,-(CH 2 ) n -OC (O)-(CH 2 ) n -,-(CH 2 ) n -C (O) N (R)-(CH 2 ) n -,-(CH 2 ) n -N (R) C (O)-(CH 2 ) n -,
  • Each of T 3 is independently covalently substituted, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted Heteroarylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted heterocyclic non-aromatic ring, quinolinyl, quinoxalinyl, quinazolinyl, iso Bicyclic aromatic, aromatic rings containing substituted or unsubstituted nitrogen-containing heterocycles having six atoms in each ring, including quinolinyl, phthalazinyl, each having five atoms, or imidazopyrimidinyl Different orientations with six atoms, including imidazoimidazolyl, imidazothiazolyl,
  • Each of T 4 is independently hydrogen, halogen, — (CH 2 ) n —CN, — (CH 2 ) n —NO 2 , — (CH 2 ) n —C (O) OH, — (CH 2 ) n ⁇ C (O) H,-(CH 2 ) n -OH,-(CH 2 ) n -C (O) -N (R) 2 , substituted or unsubstituted alkyl, halogen substituted alkyl, substituted or non- Single or polysubstituted or unsubstituted, including substituted cycloalkyl, single or polysubstituted or unsubstituted aryl, piperidinyl, piperazinyl, tetrazolyl, furanyl, pyridinyl, oxdiazolyl and isoxoxazolyl Aromatic or non-aromatic ring, substituted or unsubstituted-(CH 2
  • L 1 is C (R) or N;
  • Each L 2 is independently C ⁇ O, C ⁇ S, N, O, S, S (O) p , CHOR L , C (R L ) p , or N (R L ), wherein each R L is Independently hydrogen, halogen, -CN, -NO 2 , -C (O) OH, -C (O) H, -OH, substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or Unsubstituted aryl, or substituted or unsubstituted amino;
  • Each of p may be 1 or 2 independently.
  • the compound is 4- (3-((tetrahydrofuran-2-yl) methylamino) imidazo [1,2-a] pyrazin-2-yl) benzene-1,2-diol, N Cinnamil-4,6-dimethyl-1H-pyrazolo [3,4-b] pyridin-3-amine, N- (1- (3-isopropyl-3H-imidazo [4,5-b] pyridine 2-yl) -3-methylbutyl) cyclopropanecarboxamide, 4,6-dimethyl-N- (3- (trifluoromethyl) benzyl) -1H-pyrazolo [3,4-b] pyridine- 3-amine, N- (4-ethoxybenzyl) -4,6-dimethyl-1H-pyrazolo [3,4-b] pyridin-3-amine, 4,6-dimethyl-N-((1-propyl -1H-benzo [d] imidazol-2-yl
  • the compound is N-cinamyl-4,6-dimethyl-1H-pyrazolo [3,4-b] pyridin-3-amine, 4,6-dimethyl-N- (3 -(Trifluoromethyl) benzyl) -1H-pyrazolo [3,4-b] pyridin-3-amine, 1- (1-methyl-1H-benzo [d] imidazol-2-yl) -N- (Pyridin-3-yl) piperidine-4-carboxamide, N-cyclopentyl-1- (1-ethyl-1H-benzo [d] imidazol-2-yl) piperidine-4-carbox Amide, ethyl 2- (1- (1-methyl-1H-benzo [d] imidazol-2-yl) piperidine-4-carboxamido) acetate, 1- (1-methyl-1H-benzo [ d] imidazol-2-yl) -N- (2- (vinyloxy) e
  • the compound may be a compound according to the following examples.
  • Example 8 (Compound 57): 1- (2- (1H-Benzo [d] imidazol-2-yl) pyrrolidin-1-yl) -2- (4-methoxyphenyl) ethanone
  • Example 9 (Compound 59): 1- (3-cyclopropyl-5,6-dihydro- [1,2,4] triazolo [4,3-a] pyrazin-7 (8H) -yl) -4 -(1H-indol-3-yl) butan-1-one
  • Example 18 (Compound 94): Methyl 2- (3-((2-methyl-4-oxo-3,4,5,6-tetrahydropyrido [3,4-d] pyrimidine-7 (8H) -Yl) methyl) -1H-indol-1-yl) acetate
  • Example 19 (Compound 95): 7-((5-fluoro-3-methyl-1H-indol-2-yl) methyl) -2- (3-methylpiperidin-1-yl) -5,6 , 7,8-tetrahydropyrido [3,4-d] pyrimidin-4 (3H) -one
  • Example 25 (Compound 139): N-((1-ethyl-1H-benzo [d] imidazol-2-yl) methyl) -6-methyl-4- (trifluoromethyl) -1H-pyrazolo [ 3,4-b] pyridin-3-amine
  • Example 28 (Compound 142): 1- (4- (3H-imidazo [4,5-b] pyridin-3-yl) piperidin-1-yl) -2- (2,5-dimethoxyphenyl Ethanone
  • Example 32 (Compound 152): 1- (4- (1H-pyrazolo [3,4-b] pyridin-3-yl) piperidin-1-yl) -2- (2-fluorophenyl) ethane On
  • the compounds according to the present invention are available from commercial compound library vendors such as LeadQuest, Asinex, or can be synthesized through known synthetic methods.
  • the compounds inhibit the nuclear export function of GSK3 by binding GSK3 competitively with Axin. That is, the compounds according to the present invention inhibit GSK3 migration from the cell nucleus to the cytoplasm by binding to Axin, thereby promoting intracellular activity of GSK, or inhibiting or maintaining and increasing GSK3 concentration or activity decrease in the cell nucleus. It is useful for the treatment of diseases caused by decreasing GSK3 concentration.
  • the "diseases caused by GSK3 migration from the cell nucleus to the cytoplasm” include diseases mediated through GSK3, such as cancer, diabetes, Niemann Pick's disease type C, bipolar disorder (especially manic depression). ), Alzheimer's disease, FTDP-17 (frontal temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, and peak disease ( Pick's disease, dementia Pugilistica, AIDS associated dementia, dementia, stroke, Guam parkinsonism-dementia complex, postencephalic Parkinsonism, Frontal lobe degeneration, argyrophilic grains disease, depression, Schizophrenia, Huntington's disease, myotonic dystrophy , Inflammatory diseases such as suvacute sclerotizing panencephalitis, prion disease, Down syndrome, allergy or asthma, multiple sclerosis, rheumatoid arthritis, arteriosclerosis, inflammatory bowel disease, baldness, etc.
  • the compound according to the present invention by inhibiting the movement of the GSK3 from the cell nucleus to the cytoplasm, GSK function is inhibited to prevent and treat the disease
  • GSK function is inhibited to prevent and treat the disease
  • This can be useful. It can also be used to inhibit sperm movement and thus can be used as a male contraceptive.
  • the compounds of the present invention are useful for the prevention or treatment of cancer.
  • the compound of formula 1 or a pharmaceutically acceptable salt, prodrug, or isomer thereof may be used as a medicament.
  • the compounds can be used to prepare a medicament for treating or preventing diseases caused by GSK3 migration from the cell nucleus to the cytoplasm.
  • the pharmaceutical composition for inhibiting the growth or metastasis of cancer cells and the immune disease treatment containing the compound represented by the formula (1), a pharmaceutically acceptable salt, prodrug or isomer thereof as an active ingredient It relates to a pharmaceutical composition.
  • the composition is the compound 39, 41, 42, 45, 50, 52, 55, 57, 59, 71, 72, 78, 80 to 82, 86, 87, 94, 95, 125, 126, 128, 137-142, 145, 147, 149, 152.
  • the compounds according to the present invention can be usefully used to inhibit the development and progression of autoimmune and degenerative diseases such as rheumatoid arthritis as well as metastasis of cancer cells promoted by Wnt signal transduction.
  • the compounds according to the invention can be used by themselves or in the form of pharmaceutically acceptable acid addition salts or salts of metal complexes such as zinc, iron and the like.
  • the acid addition salt may be selected from the group consisting of hydrogen chloride, hydrogen bromide, sulfate, phosphate, maleate, acetic salt, citralate, benzoate, succinate, dried salt, ascorbate and tartalate. It is preferable.
  • compositions containing a compound according to the invention as an active ingredient may contain a pharmaceutically acceptable excipient or matrix according to conventional administration methods, dosage forms and therapeutic purposes. Mixing and dilution with a phosphorus carrier or encapsulation in a carrier in the form of a container is preferred. It can also be used in combination with other medicines that are beneficial for the treatment of other bone defects. At this time, the preparation of a physiologically acceptable protein composition having a desired pH, isotonicity, stability and the like can be used within the conventional technical scope in the field of the present invention.
  • the matrix is a biodegradable and chemical substance such as calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic acid, or polyanhydride, depending on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and contact properties; Biodegradable and biological substances such as bone or skin collagen, other pure proteins or matrix components of cells; Non-biodegradable and chemical materials such as sintered hydroxyapatite, bioglass, aluminate or other ceramics; Preference is given to using combinations of the foregoing materials such as polylactic acid, hydroxyapatite, collagen and tricalcium phosphate.
  • the present invention is not limited to the carrier.
  • Excipients in the present invention are lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, magnesium styrate, water, methylhydroxy Benzoate (methylhydroxybenzoate), propylhydroxybenzoate (propylhydroxybenzoate), talc (talc), mineral oil and the like can be used.
  • the compound of formula 1 may be used in other conventional drugs used to treat cancer, such as platinum coordination compounds such as cisplatin or carboplatin; Taxane compounds such as paclitaxel or docetaxel; Camptothecin compounds such as irinotecan or topotecan; Anti-tumor vinca alkaloids such as vinblastine, vincristine or vinorelbine; Anti-tumor nucleoside derivatives such as 5-fluorouracil, gemcitabine or capecitabine; Nitrogen mustard or nitrosourea alkylating agents such as cyclophosphamide, chlorambucil, carmustine or romustine; Anti-tumor anthracycline derivatives such as daunorubicin, doxorubicin or idarubicin; HER2 antibodies such as trastuzumab; And anti-tumor grapephytotoxin derivatives such as etoposide or ten
  • the present invention also relates to a combination of a compound of formula 1 and another agent capable of preventing or treating cancer.
  • the combination can be used as a medicament.
  • the invention also relates to a product containing (a) Formula (1) and another agent capable of preventing or treating cancer as a combination formulation for simultaneous, separate or continuous use in the prevention or treatment of cancer.
  • Different drugs may be combined in a single formulation with a pharmaceutically acceptable carrier.
  • the compound of formula 1 may be used in other conventional drugs used to treat inflammatory diseases, such as steroids, cyclooxygenase-2 inhibitors, nonsteroidal-anti-inflammatory drugs, TNF - ⁇ antibodies, for example acetyl salicylic acid, bufexamac, diclofenac potassium, schlindax, diclofenac sodium, ketorolac tromethamol, tolmethine, ibuprofen, naproxen, naproxen sodium, triaprofenic acid, flubiprofen, mefenamic acid , Niflumic acid, meclofenamate, indomethacin, proglumetacin, ketoprofen, nabumethone, paracetamol, pyricampam, tenoxycam, nimesulide, phenylbutazone, tramadol, beclomethasone Dipropionate, betamethasone, beclomethasone Dipropionate, betamethasone, beclomethas
  • the present invention also relates to a combination of a compound of formula (1), a pharmaceutically acceptable salt, prodrug, or isomer and another agent capable of preventing or treating an inflammatory disease.
  • the combination can be used as a medicament.
  • the present invention also provides a combination formulation for use simultaneously, separately or continuously in the prevention or treatment of an inflammatory disease, comprising (a) a compound of formula 1, a pharmaceutically acceptable salt, a prodrug, or an isomer thereof and (b
  • the present invention relates to a product containing another agent capable of preventing or treating an inflammatory disease. Different drugs may be combined in a single formulation with a pharmaceutically acceptable carrier.
  • the present invention provides methods for treating or preventing mammals, including humans suffering from diseases caused by GSK3 migration from the cell nucleus to the cytoplasm, more particularly immune diseases including cancer, arthritis, Alzheimer's disease, Methods of treating or preventing diabetes, particularly type 2 diabetes, or bipolar disorder are provided.
  • the method comprises administering to a mammal, including a human, an effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt, prodrug, or isomer thereof.
  • the pharmaceutical composition containing the compound according to the present invention can be prepared in a variety of formulations, it is preferable to use injectable or capsulated in a viscous form for injection into the site where the therapeutic effect is expected.
  • the dosage of the composition according to the present invention can be adjusted in consideration of the type of carrier such as the excipient or matrix used, the treatment site of the patient, the age, sex and diet of the patient, the severity of infection, the time of administration and other clinical factors.
  • a conventionally known effective amount can be administered continuously or dividedly, in consideration of weight, to observe the therapeutic effect and to determine further administration.
  • Axin2-His cDNA was obtained by PCR amplification in A549 cells and amplified at the HindIII and BamHI sites of the pcDNA3.1-hyg (+) (invitrogen) vector.
  • Axin2-His cDNA was prepared and amplified in E. coli DH5 ⁇ to obtain pcDNA3.1-Axin2-His expression vector.
  • pcDNA3.1-Axin2-His expression vector After transfection of the episomal Axin2-His expression vector, pcDNA3.1-Axin2-His expression vector, to MCF7 cells (ATCC HTB-26), 200 ⁇ g / ml of hygromycin (hygromycin) ) was treated to obtain Axin2-His overexpressing cells.
  • Triton X-100 lysis buffer was added to the obtained Axin2-His overexpressing cells to obtain cell lysate.
  • 1000 ⁇ l of Triton X-100 lysis buffer was added to 20 ⁇ l of beads, and the procedure of precipitation for 1 minute at 2000 rpm was repeated three times.
  • 10 ⁇ M of each of the cell lysate and compounds 41, 45, 78, 80, 81, 82, 95, 147 and 149 (obtained from Asinex) were added to the neutralized bead, and Triton X-100 The total volume was adjusted to 1000 ⁇ l with lysis buffer. After shaking for 5 hours at 4 °C, it was precipitated at 2000 rpm for 1 minute.
  • the primary antibodies were anti-conductin (Sigma) and anti-GSK3 ⁇ (BD Bioscience), and the protein expression level was horseradish peroxidase (HRP) -conjugated secondary antibody and enhanced chemiluminescence (ECL) detection kit ( Intron, Korea) was used to sensitize the x-ray film.
  • HRP horseradish peroxidase
  • ECL enhanced chemiluminescence
  • the present invention has an effect of providing a composition for inhibiting the development and progression of a disease caused by the GSK3 migration from the cell nucleus to the cytoplasm, which occurs due to the decrease in GSK3 concentration in the nucleus.
  • the compounds according to the present invention are useful for the treatment or prevention of various diseases caused by a decrease in the GSK3 concentration in the nucleus by inhibiting the nuclear export function of GSK3 by Axin and increasing the GSK3 concentration in the nucleus.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de GSK3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de GSK3 du noyau cellulaire au cytoplasme. Plus particulièrement, la présente invention concerne des compositions pharmaceutiques destinées à inhiber la croissance ou la métastase de cellules cancéreuses ainsi que des compositions pharmaceutiques destinées à traiter des maladies autoimmunes, contenant de nouveaux composés inhibant la translocation de GSK3 du noyau cellulaire au cytoplasme. La présente invention permet d'obtenir des compositions empêchant l'apparition et la progression de maladies causées par une réduction de la concentration de GSK3 dans le noyau et par la translocation de GSK du noyau cellulaire au cytoplasme. Les composés selon la présente invention inhibent la fonction d'exportation nucléaire de GSK3 assurée par l'axine et augmentent la concentration de GSK3 dans le noyau, d'où leur utilité pour traiter ou prévenir une pluralité de maladies causées par une réduction de la concentration de GSK3 dans le noyau.
PCT/KR2010/001444 2009-03-07 2010-03-08 Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme WO2010104306A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0019533 2009-03-07
KR20090019533 2009-03-07

Publications (2)

Publication Number Publication Date
WO2010104306A2 true WO2010104306A2 (fr) 2010-09-16
WO2010104306A3 WO2010104306A3 (fr) 2010-12-16

Family

ID=42728928

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2010/001446 WO2010104307A2 (fr) 2009-03-07 2010-03-08 Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme
PCT/KR2010/001444 WO2010104306A2 (fr) 2009-03-07 2010-03-08 Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001446 WO2010104307A2 (fr) 2009-03-07 2010-03-08 Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme

Country Status (2)

Country Link
KR (3) KR20100101054A (fr)
WO (2) WO2010104307A2 (fr)

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012077932A2 (fr) * 2010-12-07 2012-06-14 제일약품주식회사 Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant
US9012466B2 (en) 2013-03-12 2015-04-21 Arqule Inc. Substituted tricyclic pyrazolo-pyrimidine compounds
JP2015516976A (ja) * 2012-04-17 2015-06-18 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス処置のための化合物および方法
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
US9981975B2 (en) 2016-03-28 2018-05-29 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
US9994546B2 (en) 2014-02-13 2018-06-12 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
US10208048B2 (en) 2015-04-28 2019-02-19 Janssen Sciences Ireland Uc RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
US10266530B2 (en) 2016-09-09 2019-04-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US10300051B2 (en) 2014-02-13 2019-05-28 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US10329255B2 (en) 2015-08-12 2019-06-25 Incyte Corporation Salts of an LSD1 inhibitor
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10766899B2 (en) 2006-08-02 2020-09-08 Cytokinetics, Incorporated Methods for preparing substituted imidazo[4,5-b]pyrazines
US10793565B2 (en) 2016-12-22 2020-10-06 Incyte Corporation Heterocyclic compounds as immunomodulators
US10800761B2 (en) 2018-02-20 2020-10-13 Incyte Corporation Carboxamide compounds and uses thereof
US10806785B2 (en) 2016-12-22 2020-10-20 Incyte Corporation Immunomodulator compounds and methods of use
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US11014929B2 (en) 2016-09-09 2021-05-25 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US11066394B2 (en) 2019-08-06 2021-07-20 Incyte Corporation Solid forms of an HPK1 inhibitor
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
US11168093B2 (en) 2018-12-21 2021-11-09 Celgene Corporation Thienopyridine inhibitors of RIPK2
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11242343B2 (en) 2016-09-09 2022-02-08 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US11332459B2 (en) 2017-10-19 2022-05-17 Teijin Pharma Limited Benzimidazole derivatives and their uses
US11339165B2 (en) 2017-11-29 2022-05-24 Janssen Sciences Ireland Unlimited Company Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV)
US11390624B2 (en) 2019-01-29 2022-07-19 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US11407749B2 (en) 2015-10-19 2022-08-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11406624B2 (en) 2017-02-15 2022-08-09 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11465981B2 (en) 2016-12-22 2022-10-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US11491157B2 (en) 2018-01-31 2022-11-08 Janssen Sciences Ireland Unlimited Company Co Cork, IE Cycloalkyl substituted pyrazolopyrimidines having activity against RSV
US11535615B2 (en) 2015-12-22 2022-12-27 Incyte Corporation Heterocyclic compounds as immunomodulators
US11572366B2 (en) 2015-11-19 2023-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
US11608337B2 (en) 2016-05-06 2023-03-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11613536B2 (en) 2016-08-29 2023-03-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US11673894B2 (en) 2018-02-27 2023-06-13 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
US11673883B2 (en) 2016-05-26 2023-06-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US11708369B2 (en) 2018-04-23 2023-07-25 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against RSV
US11718605B2 (en) 2016-07-14 2023-08-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11873309B2 (en) 2016-06-20 2024-01-16 Incyte Corporation Heterocyclic compounds as immunomodulators

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP3381899B1 (fr) 2010-04-22 2021-01-06 Vertex Pharmaceuticals Incorporated Composé intermédiaire pour procédé de production de composés de cycloalkylcarboxamido-indole
CA3133264A1 (fr) * 2013-03-06 2014-09-12 Allergan, Inc. Utilisation d'agonistes du recepteur 2 de peptide formyle pour le traitement de maladies inflammatoires oculaires
CN107714683A (zh) * 2013-03-06 2018-02-23 阿勒根公司 用于治疗皮肤病的甲酰基肽受体2的激动剂的用途
MX2016008359A (es) * 2013-12-24 2016-12-07 Oncotartis Inc Compuestos de benzamida y nicotinamida y metodos para usar los mismos.
RS57476B9 (sr) 2014-04-15 2021-10-29 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010052137A1 (en) * 2000-03-01 2001-12-13 Trustees Of The University Of Pennsylvania Axin domain-like polypeptide inhibitors of glycogen synthase kinase 3 beta activity and activators of wnt signaling
KR20050032105A (ko) * 2002-08-02 2005-04-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 피라졸 조성물
US20070032474A1 (en) * 2003-06-10 2007-02-08 Biondi Ricardo M Use of a compound of formula 1 for making a pharmaceutical composition
KR20080038047A (ko) * 2006-10-27 2008-05-02 김정문 세포핵에서 세포질로의 ｇｓｋ３ 이동을 억제하는 방법 및물질
US20080161251A1 (en) * 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010052137A1 (en) * 2000-03-01 2001-12-13 Trustees Of The University Of Pennsylvania Axin domain-like polypeptide inhibitors of glycogen synthase kinase 3 beta activity and activators of wnt signaling
KR20050032105A (ko) * 2002-08-02 2005-04-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 피라졸 조성물
US20070032474A1 (en) * 2003-06-10 2007-02-08 Biondi Ricardo M Use of a compound of formula 1 for making a pharmaceutical composition
US20080161251A1 (en) * 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds
KR20080038047A (ko) * 2006-10-27 2008-05-02 김정문 세포핵에서 세포질로의 ｇｓｋ３ 이동을 억제하는 방법 및물질

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10766899B2 (en) 2006-08-02 2020-09-08 Cytokinetics, Incorporated Methods for preparing substituted imidazo[4,5-b]pyrazines
WO2012077932A3 (fr) * 2010-12-07 2012-09-07 제일약품주식회사 Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant
WO2012077932A2 (fr) * 2010-12-07 2012-06-14 제일약품주식회사 Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant
JP2017128596A (ja) * 2012-04-17 2017-07-27 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス処置のための化合物および方法
JP2015516976A (ja) * 2012-04-17 2015-06-18 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス処置のための化合物および方法
CN106986869A (zh) * 2012-04-17 2017-07-28 吉利德科学公司 用于抗病毒治疗的化合物和方法
US9012466B2 (en) 2013-03-12 2015-04-21 Arqule Inc. Substituted tricyclic pyrazolo-pyrimidine compounds
US9994546B2 (en) 2014-02-13 2018-06-12 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10717737B2 (en) 2014-02-13 2020-07-21 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10676457B2 (en) 2014-02-13 2020-06-09 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10300051B2 (en) 2014-02-13 2019-05-28 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US11155532B2 (en) 2014-02-13 2021-10-26 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10513493B2 (en) 2014-02-13 2019-12-24 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10174030B2 (en) 2014-02-13 2019-01-08 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US11247992B2 (en) 2014-02-13 2022-02-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10125133B2 (en) 2014-07-10 2018-11-13 Incyte Corporation Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
US10138249B2 (en) 2014-07-10 2018-11-27 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US10112950B2 (en) 2014-07-10 2018-10-30 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US10047086B2 (en) 2014-07-10 2018-08-14 Incyte Corporation Imidazopyridines and imidazopyrazines as LSD1 inhibitors
US10968221B2 (en) 2014-07-10 2021-04-06 Incyte Corporation Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US10640503B2 (en) 2014-07-10 2020-05-05 Incyte Corporation Imidazopyridines and imidazopyrazines as LSD1 inhibitors
US10556908B2 (en) 2014-07-10 2020-02-11 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
US11401272B2 (en) 2015-04-03 2022-08-02 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
US10800779B2 (en) 2015-04-03 2020-10-13 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
US10208048B2 (en) 2015-04-28 2019-02-19 Janssen Sciences Ireland Uc RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
US10611769B2 (en) 2015-04-28 2020-04-07 Janssen Sciences Ireland Unlimited Company RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
US11084826B2 (en) 2015-04-28 2021-08-10 Janssen Sciences Ireland Unlimited Company RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
US10329255B2 (en) 2015-08-12 2019-06-25 Incyte Corporation Salts of an LSD1 inhibitor
US10723700B2 (en) 2015-08-12 2020-07-28 Incyte Corporation Salts of an LSD1 inhibitor
US11498900B2 (en) 2015-08-12 2022-11-15 Incyte Corporation Salts of an LSD1 inhibitor
US11407749B2 (en) 2015-10-19 2022-08-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11572366B2 (en) 2015-11-19 2023-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US11535615B2 (en) 2015-12-22 2022-12-27 Incyte Corporation Heterocyclic compounds as immunomodulators
US11866435B2 (en) 2015-12-22 2024-01-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US9981975B2 (en) 2016-03-28 2018-05-29 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
US11608337B2 (en) 2016-05-06 2023-03-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11673883B2 (en) 2016-05-26 2023-06-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US11873309B2 (en) 2016-06-20 2024-01-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US11718605B2 (en) 2016-07-14 2023-08-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US11613536B2 (en) 2016-08-29 2023-03-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US11542265B2 (en) 2016-09-09 2023-01-03 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US11242343B2 (en) 2016-09-09 2022-02-08 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11891388B2 (en) 2016-09-09 2024-02-06 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11014929B2 (en) 2016-09-09 2021-05-25 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US10266530B2 (en) 2016-09-09 2019-04-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US11795166B2 (en) 2016-09-09 2023-10-24 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10435405B2 (en) 2016-09-09 2019-10-08 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10934288B2 (en) 2016-09-09 2021-03-02 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11465981B2 (en) 2016-12-22 2022-10-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US11787793B2 (en) 2016-12-22 2023-10-17 Incyte Corporation Heterocyclic compounds as immunomodulators
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators
US10793565B2 (en) 2016-12-22 2020-10-06 Incyte Corporation Heterocyclic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US10800768B2 (en) 2016-12-22 2020-10-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US10806785B2 (en) 2016-12-22 2020-10-20 Incyte Corporation Immunomodulator compounds and methods of use
US11339149B2 (en) 2016-12-22 2022-05-24 Incyte Corporation Heterocyclic compounds as immunomodulators
US11406624B2 (en) 2017-02-15 2022-08-09 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US11332459B2 (en) 2017-10-19 2022-05-17 Teijin Pharma Limited Benzimidazole derivatives and their uses
US11339165B2 (en) 2017-11-29 2022-05-24 Janssen Sciences Ireland Unlimited Company Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV)
US11491157B2 (en) 2018-01-31 2022-11-08 Janssen Sciences Ireland Unlimited Company Co Cork, IE Cycloalkyl substituted pyrazolopyrimidines having activity against RSV
US11731958B2 (en) 2018-02-20 2023-08-22 Incyte Corporation Carboxamide compounds and uses thereof
US10800761B2 (en) 2018-02-20 2020-10-13 Incyte Corporation Carboxamide compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11492354B2 (en) 2018-02-20 2022-11-08 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11673894B2 (en) 2018-02-27 2023-06-13 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
US11124511B2 (en) 2018-03-30 2021-09-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US11708369B2 (en) 2018-04-23 2023-07-25 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against RSV
US10906920B2 (en) 2018-05-11 2021-02-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US11414433B2 (en) 2018-05-11 2022-08-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
US11873304B2 (en) 2018-05-18 2024-01-16 Incyte Corporation Fused pyrimidine derivatives as A2A/A2B inhibitors
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US11999740B2 (en) 2018-07-05 2024-06-04 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US11866426B2 (en) 2018-08-08 2024-01-09 Incyte Corporation Benzothiazole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US11512064B2 (en) 2018-08-31 2022-11-29 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11168093B2 (en) 2018-12-21 2021-11-09 Celgene Corporation Thienopyridine inhibitors of RIPK2
US11884665B2 (en) 2019-01-29 2024-01-30 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
US11390624B2 (en) 2019-01-29 2022-07-19 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
US11066394B2 (en) 2019-08-06 2021-07-20 Incyte Corporation Solid forms of an HPK1 inhibitor
US11787784B2 (en) 2019-08-06 2023-10-17 Incyte Corporation Solid forms of an HPK1 inhibitor
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor

Also Published As

Publication number Publication date
KR20100101056A (ko) 2010-09-16
KR20100101054A (ko) 2010-09-16
WO2010104306A3 (fr) 2010-12-16
KR20100101055A (ko) 2010-09-16
WO2010104307A3 (fr) 2011-01-27
WO2010104307A2 (fr) 2010-09-16

Similar Documents

Publication Publication Date Title
WO2010104306A2 (fr) Compositions pharmaceutiques pour traiter ou prévenir des maladies causées par la translocation de gsk3 du noyau cellulaire au cytoplasme, contenant des composés inhibant la translocation de gsk3 du noyau cellulaire au cytoplasme
WO2011111880A1 (fr) Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3
EP3551610B1 (fr) Inhibiteurs bicyclo[1.1.1]pentane de la double fermeture à glissière de leucine kinase (dlk) destinés au traitement de maladie
KR100748294B1 (ko) 프로판-1,3-디온 유도체
JP5873544B2 (ja) Ｍｌｋ阻害剤および使用方法
US20080021217A1 (en) Heterocyclic inhibitors of rho kinase
JP2019507168A (ja) 新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用
JP2008517890A (ja) 治療化合物としての、イミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物ならびにそれらの類似体
KR20090120510A (ko) 단백질 키나제 억제제로서 유용한 아미노피리미딘
BR112020019824A2 (pt) Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica, método de inibição de cbp, método de inibição de p300, método de tratamento de uma doença mediada por cbp, método de tratamento de uma doença mediada por p300 e método para alcançar um efeito em um paciente
WO2021108198A1 (fr) Inhibiteurs de la protéine kinase 1 interagissant avec les récepteurs pour le traitement d'une maladie
WO2014066795A1 (fr) Composés hétérocycliques pour l'inhibition de pask
JP2022553273A (ja) 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤
AU2017223706A1 (en) Combination therapies for treatment of spinal muscular atrophy
TW201321384A (zh) 作為鈣通道阻斷劑之經取代之八氫吡咯并［１，２－ａ］吡□磺醯胺
WO2021022178A1 (fr) Pyrrolopyridines de sulfonamide substituées servant d'inhibiteurs de jak
WO2024101764A1 (fr) Dérivé d'isoindolinone ayant une structure d'amide de quinoléine et son utilisation
EP4221708A1 (fr) Inhibiteurs imidazopipérazines de protéines d'activation de la transcription
WO2022072648A1 (fr) Inhibiteurs imidazopipérazine de protéines d'activation de la transcription
CN101522643A (zh) 二环杂芳族化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10750997

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10750997

Country of ref document: EP

Kind code of ref document: A2